Sector: Healthcare · Industry: 生技醫療業 · Exchange: TPEx
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. has a strategic collaboration with CellType Inc. to accelerate evolution of CX-4945 2.0 through AI-driven drug development models. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.
Headquarters: New Taipei City, TW · Website: https://www.senhwabio.com
生華科 (6492) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Search companies · Macro trends · Industries · Product categories · Baskets